Skip to main content
SpringerLink
Log in

Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

A considerable proportion of stroke survivors are prescribed with proton pump inhibitors (PPIs). Our study indicated that PPI use is associated with an increased risk of osteoporosis, hip fracture, and vertebral fracture in stroke patients. The risk tends to increase as the cumulative doses of PPIs increase.

Introduction

A considerable proportion of stroke survivors are prescribed with proton pump inhibitors (PPIs). Our study investigated the association between PPI use and the risk of osteoporosis and fracture among stroke survivors.

Methods

A population-based propensity-matched retrospective cohort study was conducted using the National Health Insurance Research Database in Taiwan. Patients diagnosed with a new stroke between 2000 and 2012 were identified. After propensity score matching, 10,596 patients were enrolled, and 5298 patients were each assigned to the PPI user and non-user groups. Hazard ratios (HRs) were calculated for the risk of osteoporosis, hip fracture, and vertebral fractures according to PPI use or non-use. Sensitivity analyses were conducted to evaluate the dose effects of PPI.

Results

PPI use after stroke was associated with an increased risk of osteoporosis, hip fracture, or vertebral fracture, with an adjusted HR (aHR) of 1.28 (P < 0.001). The aHRs were also significant for each outcome: osteoporosis, 1.26 (P < 0.001); hip fracture, 1.18 (P = 0.048); vertebral fracture, 1.33 (P < 0.001). A pattern of dose effect was identified. For any event (osteoporosis/hip fracture/vertebral fracture), the aHR for PPI use of 1–90, 91–365, and > 365 cDDDs was 1.22 (P < 0.001), 1.27 (P < 0.001), and 1.66 (P < 0.001), respectively. For each outcome, the highest dose was associated with the highest risk, with aHR of 1.79 (P < 0.001), 1.41 (P = 0.039), and 1.82 (P < 0.001) for osteoporosis, hip fracture, and vertebral fracture, respectively. Age- and sex-stratified analyses revealed similar patterns.

Conclusions

PPI use is associated with an increased risk of osteoporosis, hip fracture, and vertebral fracture in stroke patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377(9773):1276–1287. https://doi.org/10.1016/s0140-6736(10)62349-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761–1767. https://doi.org/10.1016/s0140-6736(02)08657-9

    Article  PubMed  Google Scholar 

  3. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22(3):465–475. https://doi.org/10.1359/jbmr.061113

    Article  PubMed  Google Scholar 

  4. Carda S, Cisari C, Invernizzi M, Bevilacqua M (2009) Osteoporosis after stroke: a review of the causes and potential treatments. Cerebrovasc Dis 28(2):191–200. https://doi.org/10.1159/000226578

    Article  PubMed  Google Scholar 

  5. Callaly EL, Ni Chroinin D, Hannon N, Sheehan O, Marnane M, Merwick A, Kelly LA, Horgan G, Williams E, Harris D, Williams D, Moore A, Dolan E, Murphy S, Kelly PJ, Duggan J, Kyne L (2015) Falls and fractures 2 years after acute stroke: the North Dublin Population Stroke Study. Age Ageing 44(5):882–886. https://doi.org/10.1093/ageing/afv093

    Article  CAS  PubMed  Google Scholar 

  6. Ramnemark A, Nyberg L, Borssen B, Olsson T, Gustafson Y (1998) Fractures after stroke. Osteoporos Int 8(1):92–95. https://doi.org/10.1007/s001980050053

    Article  CAS  PubMed  Google Scholar 

  7. Yu EW, Bauer SR, Bain PA, Bauer DC (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124(6):519–526. https://doi.org/10.1016/j.amjmed.2011.01.007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Arj A, Razavi Zade M, Yavari M, Akbari H, Zamani B, Asemi Z (2016) Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis 19(9):864–868. https://doi.org/10.1111/1756-185x.12866

    Article  CAS  PubMed  Google Scholar 

  9. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K (2011) Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 106(7):1209–1218; quiz 1219. https://doi.org/10.1038/ajg.2011.113

    Article  CAS  PubMed  Google Scholar 

  10. Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28(8):951–959. https://doi.org/10.1592/phco.28.8.951

    Article  CAS  PubMed  Google Scholar 

  11. Targownik LE, Goertzen AL, Luo Y, Leslie WD (2017) Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol 112(1):95–101. https://doi.org/10.1038/ajg.2016.481

    Article  CAS  PubMed  Google Scholar 

  12. Igase M, Kohara K, Igase K, Yamashita S, Fujisawa M, Katagi R, Miki T (2013) Prevalence and associated clinical factors of GERD (gastro-esophageal reflux disease) in ischemic stroke patients. J Neurol Neurophysiol S8(004). https://doi.org/10.4172/2155-9562.S8-004

  13. Pratt S, Thompson VJ, Elkin EP, Naesdal J, Sorstadius E (2010) The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs 10(5):281–288. https://doi.org/10.2165/11584410-000000000-00000

    Article  CAS  PubMed  Google Scholar 

  14. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J (2005) Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 62(8):1217–1220. https://doi.org/10.1001/archneur.62.8.1217

    Article  PubMed  Google Scholar 

  15. Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, Naucler E, Svedberg LE (2011) Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart 97(10):797–802. https://doi.org/10.1136/hrt.2010.217547

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lin KJ, Hernandez-Diaz S, Garcia Rodriguez LA (2011) Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 141(1):71–79. https://doi.org/10.1053/j.gastro.2011.03.049

    Article  CAS  PubMed  Google Scholar 

  17. Niigaki M, Adachi K, Hirakawa K, Furuta K, Kinoshita Y (2013) Association between metabolic syndrome and prevalence of gastroesophageal reflux disease in a health screening facility in Japan. J Gastroenterol 48(4):463–472. https://doi.org/10.1007/s00535-012-0671-3

    Article  CAS  PubMed  Google Scholar 

  18. Lucas CE, Yu P, Vlahos A, Ledgerwood AM (1999) Lower esophageal sphincter dysfunction often precludes safe gastric feeding in stroke patients. Arch Surg 134(1):55–58. https://doi.org/10.1001/archsurg.134.1.55

    Article  CAS  PubMed  Google Scholar 

  19. Momosaki R, Yasunaga H, Matsui H, Fushimi K, Abo M (2016) Proton pump inhibitors versus histamine-2 receptor antagonists and risk of pneumonia in patients with acute stroke. J Stroke Cerebrovasc Dis 25(5):1035–1040. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.01.018

    Article  PubMed  Google Scholar 

  20. Wu T-Y, Majeed A, Kuo KN (2010) An overview of the healthcare system in Taiwan. London J Prim Care 3(2):115–119. https://doi.org/10.1080/17571472.2010.11493315

    Article  Google Scholar 

  21. Tsan YT, Lee CH, Wang JD, Chen PC (2012) Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 30(6):623–630. https://doi.org/10.1200/jco.2011.36.0917

    Article  PubMed  Google Scholar 

  22. Ho SW, Teng YH, Yang SF, Yeh HW, Wang YH, Chou MC, Yeh CB (2017) Association of proton pump inhibitors usage with risk of pneumonia in dementia patients. J Am Geriatr Soc 65(7):1441–1447. https://doi.org/10.1111/jgs.14813

    Article  PubMed  Google Scholar 

  23. National Health Insurance Administration, Ministy of Health and Welfare (2016) Patients with chronic diseases (refill prescriptions). https://www.nhi.gov.tw/english/Content_List.aspx?n=8499F575B188B17E&topn=1D1ECC54F86E9050. Accessed September 20 2017

  24. Chen CH, Lin CL, Kao CH (2016) Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos Int 27(6):2117–2126. https://doi.org/10.1007/s00198-016-3510-1

    Article  CAS  PubMed  Google Scholar 

  25. Lien HM, Chou SY, Liu JT (2008) Hospital ownership and performance: evidence from stroke and cardiac treatment in Taiwan. J Health Econ 27(5):1208–1223. https://doi.org/10.1016/j.jhealeco.2008.03.002

    Article  PubMed  Google Scholar 

  26. Cheng CL, Chien HC, Lee CH, Lin SJ, Yang YH (2015) Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int J Cardiol 201:96–101. https://doi.org/10.1016/j.ijcard.2015.07.075

    Article  PubMed  Google Scholar 

  27. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8

    Article  CAS  PubMed  Google Scholar 

  28. Lee HC, Chang KC, Huang YC, Lan CF, Chen JJ, Wei SH (2010) Inpatient rehabilitation utilization for acute stroke under a universal health insurance system. Am J Manag Care 16(3):e67–e74

    PubMed  Google Scholar 

  29. Liu CYHY, Chuang YL, Chen YJ, Weng WS, Liu JS, Liang KY (2006) Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey (in Chinese). J Health Manag 4(1):1–22

    CAS  Google Scholar 

  30. Chang CC, Chen YT, Hsu CY, Su YW, Chiu CC, Leu HB, Huang PH, Chen JW, Lin SJ (2017) Dipeptidyl peptidase-4 inhibitors, peripheral arterial disease, and lower extremity amputation risk in diabetic patients. Am J Med 130(3):348–355. https://doi.org/10.1016/j.amjmed.2016.10.016

    Article  CAS  PubMed  Google Scholar 

  31. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509. https://doi.org/10.2307/2670170

    Article  Google Scholar 

  32. Kapral MK, Fang J, Alibhai SM, Cram P, Cheung AM, Casaubon LK, Prager M, Stamplecoski M, Rashkovan B, Austin PC (2017) Risk of fractures after stroke: results from the Ontario Stroke Registry. Neurology 88(1):57–64. https://doi.org/10.1212/wnl.0000000000003457

    Article  PubMed  PubMed Central  Google Scholar 

  33. Batchelor F, Hill K, Mackintosh S, Said C (2010) What works in falls prevention after stroke?: a systematic review and meta-analysis. Stroke 41(8):1715–1722. https://doi.org/10.1161/strokeaha.109.570390

    Article  PubMed  Google Scholar 

  34. Lenihan CR, Sukumaran Nair S, Vangala C, Ramanathan V, Montez-Rath ME, Winkelmayer WC (2017) Proton pump inhibitor use and risk of hip fracture in kidney transplant recipients. Am J Kidney Dis 69(5):595–601. https://doi.org/10.1053/j.ajkd.2016.09.019

    Article  CAS  PubMed  Google Scholar 

  35. Goss SL, Lemons KA, Kerstetter JE, Bogner RH (2007) Determination of calcium salt solubility with changes in pH and PCO2, simulating varying gastrointestinal environments. J Pharm Pharmacol 59(11):1485–1492. https://doi.org/10.1211/jpp.59.11.0004

    Article  PubMed  Google Scholar 

  36. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118(7):778–781. https://doi.org/10.1016/j.amjmed.2005.02.007

    Article  PubMed  Google Scholar 

  37. Costa-Rodrigues J, Reis S, Teixeira S, Lopes S, Fernandes MH (2013) Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J 280(20):5052–5064. https://doi.org/10.1111/febs.12478

    Article  CAS  PubMed  Google Scholar 

  38. Lam JR, Schneider JL, Zhao W, Corley DA (2013) Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310(22):2435–2442. https://doi.org/10.1001/jama.2013.280490

    Article  CAS  PubMed  Google Scholar 

  39. Green RH, Allen L, Bjørke-Monsen A-L, Brito A, Jean-Louis Guéant W, Miller JM, Molloy A, Nexo E, Stabler S, Toh B-H, Magne Ueland P, Yajnik C (2017) Vitamin B12 deficiency. Nat Rev Dis Primers 3:17041. https://doi.org/10.1038/nrdp.2017.41

    Article  Google Scholar 

  40. Herrmann M, Widmann T, Herrmann W (2005) Homocysteine—a newly recognised risk factor for osteoporosis. Clin Chem Lab Med 43(10):1111–1117. https://doi.org/10.1515/cclm.2005.194

    CAS  PubMed  Google Scholar 

  41. Yang J, Hu X, Zhang Q, Cao H, Wang J, Liu B (2012) Homocysteine level and risk of fracture: a meta-analysis and systematic review. Bone 51(3):376–382. https://doi.org/10.1016/j.bone.2012.05.024

    Article  CAS  PubMed  Google Scholar 

  42. Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, Prince RL (2014) Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res 29(11):2489–2497. https://doi.org/10.1002/jbmr.2279

    Article  PubMed  Google Scholar 

  43. Stabler SP (2013) Vitamin B12 deficiency. N Engl J Med 368(2):149–160. https://doi.org/10.1056/NEJMcp1113996

    Article  CAS  PubMed  Google Scholar 

  44. Lévesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340. https://doi.org/10.1136/bmj.b5087

  45. Wang WJ, Chao CT, Huang YC, Wang CY, Chang CH, Huang TM, Lai CF, Huang HY, Shiao CC, Chu TS, Chen YM, Wu VC, Ko WJ, Wu KD (2014) The impact of acute kidney injury with temporary dialysis on the risk of fracture. J Bone Miner Res 29(3):676–684. https://doi.org/10.1002/jbmr.2061

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Shu-Man Lin and Shih-Hsien Yang contributed equally to this work.

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, Buddhist Tzu Chi General Hospital, Hualien, Taiwan

    S.-M. Lin, S.-H. Yang & C.-C. Liang

  2. School of Medicine, Tzu Chi University, Hualien, Taiwan

    S.-H. Yang

  3. Department of Family Medicine, Buddhist Tzu Chi General Hospital, No. 707, Sec. 3, Chung Yang Rd, Hualien, 97002, Taiwan

    H.-K. Huang

Authors
  1. S.-M. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S.-H. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C.-C. Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H.-K. Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H.-K. Huang.

Ethics declarations

This study protocol was approved by the Institutional Review Board of Tzu Chi Medical Center (REC No. IRB104-131C).

Conflicts of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, SM., Yang, SH., Liang, CC. et al. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos Int 29, 153–162 (2018). https://doi.org/10.1007/s00198-017-4262-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-017-4262-2

Keywords

Search

Navigation